Emil D Kakkis - Net Worth and Insider Trading
Emil D Kakkis Net Worth
The estimated net worth of Emil D Kakkis is at least $118 Million dollars as of 2024-05-12. Emil D Kakkis is the President & CEO of Ultragenyx Pharmaceutical Inc and owns about 2,803,755 shares of Ultragenyx Pharmaceutical Inc (RARE) stock worth over $115 Million. Emil D Kakkis is also the Chief Medical Officer of Biomarin Pharmaceutical Inc and owns about 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $3 Million. Details can be seen in Emil D Kakkis's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Emil D Kakkis has not made any transactions after 2024-02-07 and currently still holds the listed stock(s).
Transaction Summary of Emil D Kakkis
Emil D Kakkis Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Emil D Kakkis owns 2 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , and Biomarin Pharmaceutical Inc (BMRN) .
Click here to see the complete history of Emil D Kakkis’s form 4 insider trades.
Insider Ownership Summary of Emil D Kakkis
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2024-02-07 | director & 10 percent owner & President & CEO |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | SVP & Business Operations |
Emil D Kakkis Latest Holdings Summary
Emil D Kakkis currently owns a total of 2 stocks. Among these stocks, Emil D Kakkis owns 2,803,755 shares of Ultragenyx Pharmaceutical Inc (RARE) as of February 7, 2024, with a value of $115 Million and a weighting of 97.28%. Emil D Kakkis also owns 39,621 shares of Biomarin Pharmaceutical Inc (BMRN) as of March 2, 2009, with a value of $3 Million and a weighting of 2.72%.
Latest Holdings of Emil D Kakkis
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2024-02-07 | 2,803,755 | 40.90 | 114,673,580 |
| BMRN | Biomarin Pharmaceutical Inc | 2009-03-02 | 39,621 | 81.03 | 3,210,490 |
Holding Weightings of Emil D Kakkis
Emil D Kakkis Form 4 Trading Tracker
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 11 transactions in Ultragenyx Pharmaceutical Inc (RARE) over the past 5 years, including 1 buys and 10 sells. The most-recent trade in Ultragenyx Pharmaceutical Inc is the sale of 30,000 shares on February 7, 2024, which brought Emil D Kakkis around $1 Million.
According to the SEC Form 4 filings, Emil D Kakkis has made a total of 0 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 7,897 shares on March 2, 2009, which brought Emil D Kakkis around $92,395.
Insider Trading History of Emil D Kakkis
- 1
Emil D Kakkis Trading Performance
GuruFocus tracks the stock performance after each of Emil D Kakkis's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Emil D Kakkis is -14.31%. GuruFocus also compares Emil D Kakkis's trading performance to market benchmark return within the same time period. The performance of stocks bought by Emil D Kakkis within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Emil D Kakkis's insider trading performs compared to the benchmark.
Performance of Emil D Kakkis
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.47 | | | | | |
| Relative Return to S&P 500(%) | -0.34 | | | | | |
Emil D Kakkis Ownership Network
Emil D Kakkis Owned Company Details
What does Ultragenyx Pharmaceutical Inc do?
Who are the key executives at Ultragenyx Pharmaceutical Inc?
Emil D Kakkis is the director & 10 percent owner & President & CEO of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include EVP and Chief Medical Officer Eric Crombez , CBO & Senior Vice President Thomas Richard Kassberg , and EVP and General Counsel Karah Herdman Parschauer .
Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary
Over the past 18 months, Emil D Kakkis made 4 insider transaction in Ultragenyx Pharmaceutical Inc (RARE) with a net sale of 127,435. Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 5,605 shares made by Theodore Alan Huizenga , a net sale of 54,366 shares made by Thomas Richard Kassberg , and a net sale of 14,737 shares made by Erik Harris .
In summary, during the past 3 months, insiders sold 39,487 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 39,487 shares. During the past 18 months, 243,647 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 243,647 shares.
Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ultragenyx Pharmaceutical Inc Insider Transactions
Emil D Kakkis Mailing Address
Above is the net worth, insider trading, and ownership report for Emil D Kakkis. You might contact Emil D Kakkis via mailing address: C/o Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato Ca 94949.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
